Overview

Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

A prospective, randomised, open label study of 3 clinically licensed treatments for ACS to assess the effects of these treatments on blood tests of endogenous fibrinolysis. 50 patients will be randomised to each of the 3 treatment arms in 1:1:1 ratio. Patients will receive the randomised treatment for 1 month after their index admission with ACS.

Phase:

Phase 4

Details

Lead Sponsor:

East and North Hertfordshire NHS Trust

Collaborator:

University of Hertfordshire

Treatments:

Adenosine
Clopidogrel
Rivaroxaban
Ticagrelor
Ticlopidine